ozanimod

Ozanimod Could Drive Celgene’s Long-Term Growth
Ozanimod Could Drive Celgene’s Long-Term Growth
Market Realist
ozanimod
Celgene
Flag link:
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
Flag link:
Celgene touts ozanimod MS data, but disability benefit weak over rival med
Celgene touts ozanimod MS data, but disability benefit weak over rival med
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Biogen
Avonex
Flag link:
Celgene highlights MS drug in diversification push
Celgene highlights MS drug in diversification push
BioPharma Dive
Celgene
MS
multiple sclerosis
ozanimod
Flag link:
3 Big Biotech Stocks With Big-Time Catalysts
3 Big Biotech Stocks With Big-Time Catalysts
Motley Fool
Regeneron
Praluent
Amgen
biosimilars
Amjevita
Humira
ABP-215
Avastin
ABP-980
Herceptin
Celgene
ozanimod
Flag link:
Ozanimod Safety Still A Question Mark For Celgene
Ozanimod Safety Still A Question Mark For Celgene
Seeking Alpha
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?
Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?
Motley Fool
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial
Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial
TheStreet.com
Celgene
ozanimod
clinical trials
MS
multiple sclerosis
Flag link:
What's Next For Celgene
What's Next For Celgene
Motley Fool
Celgene
JPMHC 2017
Otezla
ozanimod
Revlimid
Pomalyst
Flag link:
Did Biogen Just Throw in the Towel to Celgene?
Did Biogen Just Throw in the Towel to Celgene?
Motley Fool
Biogen
Celgene
MT-1303
autoimmune disease
ozanimod
Flag link:
Celgene Boldly Targeting $6 Billion (or More) in New Business
Celgene Boldly Targeting $6 Billion (or More) in New Business
Motley Fool
Celgene
Otezla
autoimmune disease
ozanimod
Mongersen
Flag link:
Biogen quietly whisks away its $544M autoimmune rival to Celgene
Biogen quietly whisks away its $544M autoimmune rival to Celgene
Endpoints
Biogen
Celgene
autoimmune disease
amiselimod
ozanimod
Flag link:
7 Reasons Celgene Is the Best Bet in Biotech
7 Reasons Celgene Is the Best Bet in Biotech
Motley Fool
Celgene
ozanimod
CAR-T
CC-122
CC-220
demcizumab
Mongersen
AVL292
Flag link:
Celgene Is Building an Autoimmune Empire -- and No One Is Talking About It
Celgene Is Building an Autoimmune Empire -- and No One Is Talking About It
Motley Fool
Celgene
autoimmune disease
Otezla
ozanimod
GED-0301
Flag link:
The Most Exciting Drug in Celgene's Pipeline
The Most Exciting Drug in Celgene's Pipeline
Motley Fool
Celgene
ozanimod
autoimmune disease
Flag link:
Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons
Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons
TheStreet.com
Celgene
Crohn's Disease
GED-0301
Otezla
ozanimod
Flag link:
Arena Investors Hope Celgene Trial A Harbinger For Future Returns
Arena Investors Hope Celgene Trial A Harbinger For Future Returns
Seeking Alpha
Arena Pharmaceuticals
Celgene
ozanimod
APD334
ulcerative colitis
Flag link:
Is This a Potential $7 Billion Waste for Celgene Corporation?
Is This a Potential $7 Billion Waste for Celgene Corporation?
Motley Fool
Celgene
Biogen
multiple sclerosis
ozanimod
Receptos
Flag link:
The Best Celgene Corporation Headlines in 2015
The Best Celgene Corporation Headlines in 2015
Motley Fool
Celgene
ozanimod
Receptos
Flag link: